Safety and efficacy of Diquas eye drops 3%

Post marketing surveillance on safety and efficacy of Diquas eye drops 3% in Korean patients in accordance with 'Regulation for re-examination of new drugs, etc."

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003134

Enrollment

Registered

2018-08-28

Start date

2014-03-11

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Diquas 3&#37

ophthalmic solution, six times a day, for more than 4 weeks, topical eye drop application

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with dry eye syndrome

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Ocular surface staining score and tear film breakup time	—

Secondary

Measure	Time frame
Subjective dry eye symptom	—

Countries

Korea, Republic of

Contacts

Public ContactJoo Youn Oh

Seoul National University Hospital

jooyounoh77@gmail.com+82-2-2072-0027

Outcome results